Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound ganoderma lucidum granules
- Development stage
- Unknown
- Lead developer
- Shenghua Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Compound Ganoderma Lucidum Granules is a Traditional Chinese Medicine (TCM) product developed by Jiangsu Shenhua Pharmaceutical. It is a combination therapy primarily containing extracts from *Ganoderma lucidum* (Reishi mushroom), *Poria cocos*, and *Polygala tenuifolia*. The formulation is indicated for the treatment of neurasthenia and related symptoms, including insomnia, dizziness, headache, and excessive dreaming. It functions by nourishing the heart and calming the spirit (Anshen), a traditional approach to managing neurological and psychological distress. While the specific molecular mechanisms are complex due to the multi-component nature of the herbal extracts, the product is recognized for its sedative and potential immunomodulatory properties. It is approved in China as a pharmaceutical product and is typically administered orally in granule form.
- Brand names
- Shenhua
- Other names
- Fufang Lingzhi KeliCompound Reishi Granules
Beyond the preview
Go deeper on compound ganoderma lucidum granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound ganoderma lucidum granules.